Neurocrine Biosciences, Inc. (NBIX)
Largest Insider Buys in Sector
NBIX Stock Price History Chart
NBIX Stock Performance
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA …
Insider Activity of Neurocrine Biosciences, Inc.
Over the last 12 months, insiders at Neurocrine Biosciences, Inc. have bought $0 and sold $101.93M worth of Neurocrine Biosciences, Inc. stock.
On average, over the past 5 years, insiders at Neurocrine Biosciences, Inc. have bought $0 and sold $51.42M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 59,000 shares for transaction amount of $351,345 was made by BVF PARTNERS L P/IL (10 percent owner) on 2011‑10‑12.
List of Insider Buy and Sell Transactions, Neurocrine Biosciences, Inc.
| 2024-12-17 | Sale | Chief Regulatory Officer | 1,091 0.0011% | $135.00 | $147,285 | -0.93% | ||
| 2024-11-29 | Sale | Chief Scientific Officer | 2,331 0.0023% | $126.29 | $294,373 | +1.10% | ||
| 2024-10-03 | Sale | Chief Corp. Affairs Officer | 1,295 0.0013% | $113.66 | $147,190 | +12.06% | ||
| 2024-09-13 | Sale | Chief Corp. Affairs Officer | 3,461 0.0034% | $121.88 | $421,828 | +0.05% | ||
| 2024-08-15 | Sale | director | 14,250 0.0141% | $146.69 | $2.09M | 0.00% | ||
| 2024-08-13 | Sale | director | 11,570 0.0117% | $150.43 | $1.74M | 0.00% | ||
| 2024-08-13 | Sale | Chief Financial Officer | 14,100 0.0143% | $150.38 | $2.12M | 0.00% | ||
| 2024-08-13 | Sale | Chief Regulatory Officer | 7,143 0.0072% | $150.10 | $1.07M | 0.00% | ||
| 2024-08-06 | Sale | Chief Regulatory Officer | 273 0.0003% | $147.70 | $40,322 | -14.63% | ||
| 2024-08-01 | Sale | Chief Legal Officer | 2,996 0.003% | $154.01 | $461,423 | -18.35% | ||
| 2024-08-01 | Sale | Chief Human Resources Officer | 12,632 0.0126% | $153.26 | $1.94M | -18.35% | ||
| 2024-07-16 | Sale | director | 930 0.001% | $150.03 | $139,530 | -14.83% | ||
| 2024-07-16 | Sale | Chief Legal Officer | 7,004 0.0077% | $150.00 | $1.05M | -14.83% | ||
| 2024-07-16 | Sale | Chief Financial Officer | 900 0.001% | $150.04 | $135,037 | -14.83% | ||
| 2024-07-16 | Sale | Chief Human Resources Officer | 900 0.001% | $150.04 | $135,036 | -14.83% | ||
| 2024-07-16 | Sale | Chief Regulatory Officer | 2,857 0.0031% | $150.03 | $428,627 | -14.83% | ||
| 2024-07-01 | Sale | Chief Human Resources Officer | 10,000 0.0103% | $140.19 | $1.4M | 0.00% | ||
| 2024-07-01 | Sale | Chief Regulatory Officer | 272 0.0003% | $138.11 | $37,566 | 0.00% | ||
| 2024-05-31 | Sale | Chief Regulatory Officer | 273 0.0003% | $136.55 | $37,278 | -6.20% | ||
| 2024-05-29 | Sale | director | 40,000 0.0394% | $133.46 | $5.34M | -5.60% |
Insider Historical Profitability
| BVF PARTNERS L P/IL | 10 percent owner | 3527700 3.4843% | $135.42 | 36 | 10 | <0.0001% |
| MITCHELL W THOMAS | director | 1000 0.001% | $135.42 | 2 | 7 | +29.05% |
Institutional Investor Ownership
| BlackRock | $1.9B | 13.67 | 13.76M | +0.83% | +$15.6M | 0.04 | |
| The Vanguard Group | $1.37B | 9.87 | 9.93M | +2.27% | +$30.42M | 0.03 | |
| State Street | $550.3M | 3.97 | 3.99M | -1.81% | -$10.12M | 0.02 | |
| JPMorgan Chase | $316.54M | 2.28 | 2.3M | +32.24% | +$77.18M | 0.03 | |
| Renaissance Technologies | $310.55M | 2.24 | 2.25M | +13.23% | +$36.29M | 0.49 |